Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Tibremciclib (BPI-16350) in Advanced Solid Tumors
NCT03791112Phase 1Active, not recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Jul 2019
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tibremciclib in solid tumor (advanced stage) (6 arms), sponsored by Betta Pharmaceuticals. Primary endpoint: Participants with Adverse Events at 24 months. Started Jul 2019; status: active, not recruiting.
02
Drugs
tibremciclib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03791112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03791112.